A Subgroup of Patients With Hospital-acquired Pneumonia Do Not Require Broad-spectrum Gram-negative Antimicrobial Coverage.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 26 02 2020
accepted: 06 04 2020
pubmed: 9 4 2020
medline: 29 4 2021
entrez: 9 4 2020
Statut: ppublish

Résumé

Among 200 patients developing hospital-acquired pneumonia (HAP) outside the intensive care unit, 61% were treated empirically without broad-spectrum Gram-negative coverage, with clinical cure in 69.7%. Lower disease severity markers (systemic inflammatory response syndrome, hypoxia, tachypnoea, neutrophilia) and the absence of diabetes mellitus and prior doxycycline treatment (but not the time to HAP onset) identified patients not requiring broad-spectrum Gram-negative coverage.

Identifiants

pubmed: 32266388
pii: 5817567
doi: 10.1093/cid/ciaa391
pmc: PMC7744989
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e710-e713

Subventions

Organisme : Wellcome Trust
ID : 214178/Z/18/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Auteurs

Clark D Russell (CD)

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom.
National Health Service Lothian Infection Service, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom.
National Health Service Lothian Infection Service, Clinical Microbiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Ed Whittaker (E)

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom.

Dominic P Dee (DP)

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom.

Eilidh Farquhar (E)

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom.

Alba Saenz de Villaverde (A)

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom.

Morgan H Evans (MH)

National Health Service Lothian Infection Service, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom.

Ian F Laurenson (IF)

National Health Service Lothian Infection Service, Clinical Microbiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Claire L Mackintosh (CL)

National Health Service Lothian Infection Service, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom.

Muge Cevik (M)

National Health Service Lothian Infection Service, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, United Kingdom.
National Health Service Lothian Infection Service, Clinical Microbiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Infection and Global Health Research, School of Medicine, University of St Andrews, Fife, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH